C4 Therapeutics (CCCC) Short-term Investments (2020 - 2026)

C4 Therapeutics' Short-term Investments history runs 7 years deep, the most recent figure standing at $174.4 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 6.47% year-over-year to $174.4 million; the TTM figure through Mar 2026 stood at $174.4 million (up 6.47% YoY), while the FY2025 annual figure was $173.9 million, down 8.17% from the prior year.
• Short-term Investments was $174.4 million for Q1 2026 at C4 Therapeutics, roughly flat from $173.9 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $264.1 million in Q3 2022 to a low of $127.1 million in Q4 2023.
• Historically, Short-term Investments has averaged $191.7 million across 5 years, with a median of $189.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments tumbled 48.42% in 2023, then soared 49.03% in 2024.
• A 5-year view of Short-term Investments shows it stood at $246.4 million in 2022, then sank by 48.42% to $127.1 million in 2023, then soared by 49.03% to $189.4 million in 2024, then retreated by 8.17% to $173.9 million in 2025, then advanced by 0.27% to $174.4 million in 2026.
• The last three Short-term Investments figures came in at $174.4 million (Q1 2026), $173.9 million (Q4 2025), and $133.1 million (Q3 2025), per Business Quant data.